Tyrosine Kinase Inhibitors: all 10,744 studies that test it

Page 84 of 108. Open to participants first (1,949), then studies with results posted, then the rest; newest registration first within each.

• Pazopanib for Treating Uterine LeiomyosarcomaWithdrawnNCT02378142Phase 2
• Phase II Study of Icotinib With Concurrent Radiotherapy in Elderly Patients With Esophageal CancerStatus unknownNCT02375581Phase 2
• Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR MutationsStatus unknownNCT02375022Phase 2
• A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLCCompletedNCT02374645Phase 1
• A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar CholangiocarcinomaTerminatedNCT02374489Phase 2
• A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant MesotheliomaTerminatedNCT02372227Phase 1
• A Study of LY2801653 in Healthy Participants Who Are Not Able to Have ChildrenCompletedNCT02370485Phase 1
• Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue SarcomaWithdrawnNCT02367651Phase 2
• A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)Active, not recruitingNCT02365441Phase 2
• Treatment of Cervical Spinal Cord Injury With Imatinib - a Safety and Feasibility StudyStatus unknownNCT02363361Phase 2
• Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line TherapyTerminatedNCT02362230Phase 2
• A Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular CarcinomaCompletedNCT02358395Phase 1
• A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)SuspendedNCT02356991Phase 2
• Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell LymphomaTerminatedNCT02356458Phase 1/2
• Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating MutationsWithdrawnNCT02355431Phase 2
• A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular CarcinomaCompletedNCT02354898Phase 1
• A Phase II Trial of Afatinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of EsophagusStatus unknownNCT02353936Phase 2
• Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic CancerCompletedNCT02349867Phase 1
• Phase II Study of Pazopanib and Topotecan in Cervical CancerWithdrawnNCT02348398Phase 2
• Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL PatientsCompletedNCT02345863Phase 2
• C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal CancerWithdrawnNCT02344810Phase 1/2
• Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem MalignanciesWithdrawnNCT02343679Phase 2
• SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)WithdrawnNCT02342600Phase 2
• Safety and Clinical Activity of Lapatinib in Patients With HER2-positive Refractory Advanced CancerCompletedNCT02342587Phase 2
• Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)TerminatedNCT02342353Phase 1
• A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on OlaparibCompletedNCT02340611Phase 2
• Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior TrastuzumabCompletedNCT02338245Phase 2
• Ph 1, Single-Center, Safety, Tolerability & Pharmacokinetic Study of KX2 391 Ointment in Subj. w Actinic KeratosisCompletedNCT02337205Phase 1
• Antimicrobial Photodynamic Therapy Applied in Orthodontic. Orthodontic Patients.CompletedNCT02337192Phase 1
• A Study of Famitinib in Patients With Gastrointestinal Stromal TumorStatus unknownNCT02336724Phase 2
• First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02335814Phase 1
• Open-label PK Study to Evaluate Lansoprazole and Neratinib in Healthy SubjectsCompletedNCT02334501Phase 1
• Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)Status unknownNCT02332512Phase 3
• Study of Anlotinib in Patients With Metastatic Colorectal Cancer（mCRC）(ALTER0703)CompletedNCT02332499Phase 2/3
• Sorafenib Drug Drug Interaction Study in Healthy Male SubjectsCompletedNCT02332031Phase 1
• Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma MultiformeActive, not recruitingNCT02331498Phase 1/2
• Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010 in Patients With EGFR T790M Positive NSCLCStatus unknownNCT02330367Phase 1/2
• A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal CarcinomaStatus unknownNCT02328261Phase 2
• Safety, Tolerability & PK of KX2-361 in Subjects w Adv. Malignancies Refractory to Conventional TherapiesCompletedNCT02326441Phase 1
• Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular ResponseCompletedNCT02326311Phase 3
• Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIBTerminatedNCT02326285Phase 2/3
• Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC PatientsStatus unknownNCT02324803Phase 2
• Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver CancerTerminatedNCT02323906Phase 1
• Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung CancerActive, not recruitingNCT02321501Phase 1
• A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLCStatus unknownNCT02321293Phase 1
• Cohort Study of the Clinical Course of Macular Diseases in KagawaStatus unknownNCT02321267Phase 4
• A Food Effect Phase I Study of the Sulfatinib in Healthy Subjects (HMPL-012)CompletedNCT02320409Phase 1
• Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid LeukemiaStatus unknownNCT02317159Phase 4
• A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients （FRESCO)CompletedNCT02314819Phase 3
• Deciphering Antitumour Response and Resistance With INtratumour HeterogeneityCompletedNCT02314481Phase 2
• Ph Ib/BGJ398/Cervix and Other Solid TumorsWithdrawnNCT02312804Phase 1
• Efficacy and Safety of Concurrent TACE and Sorafenib in Patients With HCC and Extrahepatic Metastasis (COTSOM Study)Status unknownNCT02311205Phase 2
• Study of Ibrutinib in Relapsed and Refractory T-cell LymphomaCompletedNCT02309580Phase 1
• Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic MelanomaCompletedNCT02308553Phase 1/2
• Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard TherapyCompletedNCT02307500Phase 2
• A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell CancerWithdrawnNCT02307474Not applicable
• Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural MesotheliomaCompletedNCT02303899Phase 2
• Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid TumoursCompletedNCT02303028Phase 1/2
• SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerActive, not recruitingNCT02299999Phase 2
• Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)CompletedNCT02299505Phase 1
• Curcumin Addition to Antipsychotic Treatment in Chronic Schizophrenia PatientsCompletedNCT02298985Phase 4
• Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory NeuroblastomaActive, not recruitingNCT02298348Phase 1
• Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 MutationsTerminatedNCT02298166Phase 3
• A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung CancerWithdrawnNCT02297425Phase 2
• Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.CompletedNCT02292550Phase 1
• Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular CancerCompletedNCT02292173Phase 1
• Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid CancerWithdrawnNCT02289144Phase 2
• Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular CancerWithdrawnNCT02288507Phase 1
• Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent TreatmentWithdrawnNCT02287727Phase 2
• Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene MutationStatus unknownNCT02283424Phase 4
• Blood Detection of EGFR Mutation For Iressa TreatmentStatus unknownNCT02282267Not applicable
• The Effects of Repeated Bouts of Downhill Running and Curcumin Supplementation on Arterial Stiffness During RecoveryWithdrawnNCT02281981Not applicable
• Nilotinib in Cognitively Impaired Parkinson Disease Patients 001CompletedNCT02281474Phase 1
• Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG)TerminatedNCT02279576Phase 2
• A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051bCompletedNCT02279433Phase 1
• BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial CarcinomaStatus unknownNCT02278978Phase 2
• Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic CancerStatus unknownNCT02278458Phase 1
• Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver MutationsWithdrawnNCT02277457Early Phase 1
• Curcumin in Pediatric Ulcerative ColitisWithdrawnNCT02277223Phase 3
• Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung CancerStatus unknownNCT02274337Phase 1/2
• Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line TreatmentWithdrawnNCT02274012Phase 2
• Study of Chemotherapy Plus Icotinib to Treat EGFR Mutation-positive Non-small-cell Lung CancerStatus unknownNCT02272127Phase 2
• A Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy ParticipantsCompletedNCT02271438Phase 1
• Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic MalignanciesCompletedNCT02270788Phase 1
• Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed GlioblastomaCompletedNCT02270034Phase 1
• Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell LymphomaTerminatedNCT02269085Phase 1
• Efficacy and Safety of Dacomitinib in the Treatment of Skin Squamous Cell CancerStatus unknownNCT02268747Phase 2
• Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal TumorsWithdrawnNCT02268435Phase 1
• Treatment-free Remission Accomplished With Dasatinib in Patients With CMLStatus unknownNCT02268370Phase 2
• Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine TumorsCompletedNCT02267967Phase 1
• Safety and Tolerability of ODM-203 in Subjects With Advanced Solid TumoursCompletedNCT02264418Phase 1
• The Tolerability and Effects of AZD0530 in Individuals With or Without a Family History of AlcoholismCompletedNCT02262026Phase 1
• Phase II Study on Axitinib in Advanced Solitary Fibrous TumorCompletedNCT02261207Phase 2
• Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)CompletedNCT02260505Phase 3
• Sorafenib Plus Vitamin K1 Versus Sorafenib in Advanced Hepatocellular CarcinomaCompletedNCT02259647Not applicable
• Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in PhaseTerminatedNCT02258607Phase 1
• Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung CancerTerminatedNCT02257619Phase 2
• Curcumin Associated With Thiopurin in the Prevention of Post-op Recurrence in Crohn DiseaseCompletedNCT02255370Phase 3
• Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL PatientsCompletedNCT02253277Phase 1
• A Study of Safety and Pharmacokinetics of Volitinib With Docetaxel in Patients With Advanced Gastric CancerCompletedNCT02252913Phase 1

← Tyrosine Kinase Inhibitors overview